Novartis (VTX:NOVN) has been given a CHF 89 price objective by investment analysts at Baader Bank in a research report issued on Thursday. The firm presently has a “buy” rating on the stock. Baader Bank’s price target points to a potential upside of 13.55% from the stock’s previous close.
A number of other equities analysts also recently commented on NOVN. Barclays set a CHF 70 target price on Novartis and gave the company a “sell” rating in a research note on Monday, June 25th. JPMorgan Chase & Co. set a CHF 84 target price on Novartis and gave the company a “neutral” rating in a research note on Tuesday, July 17th. Deutsche Bank set a CHF 89 price target on Novartis and gave the company a “neutral” rating in a report on Tuesday, July 3rd. Cfra set a CHF 88 price target on Novartis and gave the company a “buy” rating in a report on Friday, June 29th. Finally, Berenberg Bank set a CHF 90 price target on Novartis and gave the company a “neutral” rating in a report on Friday, June 29th. Eleven analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. Novartis has an average rating of “Hold” and a consensus price target of CHF 89.19.
Shares of NOVN stock opened at CHF 78.38 on Thursday. Novartis has a 52 week low of CHF 72.45 and a 52 week high of CHF 88.30.
Novan, Inc, a clinical-stage biotechnology company, focuses on the development and commercialization of nitric oxide-based therapies to treat dermatological and oncovirus-mediated diseases. Its clinical stage product candidates include SB204, a topical monotherapy that is in Phase III pivotal clinical trials for the treatment of acne vulgaris; and SB206, a topical antiviral gel, which is in Phase III pivotal trials for the treatment of patients with external genital warts, and Phase II clinical trial for the treatment of molluscum contagiosum.
See Also: Fundamental Analysis and Choosing Stocks
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.